688293.SHG Shanghai OPM Biosciences Co. Ltd. A
- Market cap
- CNY 9.26B
- P/E
- 203.2x
- P/B
- 2.58x
- ROE
- 7.9%
- Dividend yield
- 0.53%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 688293.SHG undervalued?
Graham numberThe Graham number of Shanghai OPM Biosciences Co. Ltd. A cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Shanghai OPM Biosciences Co. Ltd. A fundamental analysis
No fundamental analysis for Shanghai OPM Biosciences Co. Ltd. A yet.
Shanghai OPM Biosciences Co. Ltd. A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Shanghai OPM Biosciences Co. Ltd. A
Shanghai OPM Biosciences Co., Ltd. provides cell culture media and CDMO services in China and internationally. The company offers cell culture media and feed supplements, such as OPM's CHO-Platform, OPM-293 Platform, OPM-Vac platform, OPM-Hybri Platform, VegaCHO media and feeds, as well as customized cell culture media development services. It also provides end-to-end biologics CDMO services, such as antibody discovery, stable cell line development, cell banking, upstream pr…
Full company profileShanghai OPM Biosciences Co. Ltd. A financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Shanghai OPM Biosciences Co. Ltd. A annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 125M | 213M | 294M | 243M | 297M | 355M | 907M |
| Gross Profit | 57.5M | 127M | 188M | 143M | 158M | 180M | 418M |
| Operating Income | 10.0M | 60.6M | 104M | 33.2M | 18.0M | 37.8M | 156M |
| EBITDA | - | - | 158M | 102M | 85.6M | 102M | 268M |
| Net Income | 11.7M | 60.4M | 105M | 54.0M | 21.1M | 41.7M | 248M |
| EPS | 0.14 | 0.70 | 0.92 | 0.47 | 0.18 | 0.37 | 1.74 |
| Balance Sheet | |||||||
| Total Assets | 617M | 747M | 2.35B | 2.30B | 2.29B | 2.25B | 3.74B |
| Total Liabilities | 123M | 185M | 163M | 144M | 191M | 148M | 600M |
| Shareholders' Equity | 494M | 562M | 2.18B | 2.16B | 2.10B | 2.10B | 3.14B |
| Cash & Short-term Investments | 309M | 310M | 1.51B | 1.28B | 891M | 787M | 979M |
| Cash Flow | |||||||
| Operating Cash Flow | 3.20M | 115M | 112M | 58.0M | 69.2M | 103M | - |
| Capital Expenditure | 36.2M | 99.2M | 147M | 77.5M | 121M | 56.1M | 31.2M |
| Free Cash Flow | -33.0M | 15.4M | -35.3M | -19.6M | -51.6M | 47.3M | 180M |
| Ratios | |||||||
| ROE | 2.4% | 10.7% | 4.8% | 2.5% | 1.0% | 2.0% | 7.9% |
| ROA | 1.9% | 8.1% | 4.5% | 2.3% | 0.9% | 1.9% | 6.6% |
| Net Profit Margin | 9.3% | 28.4% | 35.8% | 22.2% | 7.1% | 11.7% | 27.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Shanghai OPM Biosciences Co. Ltd. A dividends
- Dividend yield
- 0.53%
- Forward dividend
- 0.40 CNY
- Payout ratio
- 117.1%
- Ex-dividend date
- Oct 27, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 48.8M | 0.43 | 117.1% |
| 2024 | CNY 51.2M | 0.45 | 243.3% |
| 2023 | CNY 73.8M | 0.64 | 136.6% |
| 2022 | CNY 2.08M | 0.02 | 2.0% |
| 2021 | CNY 1.80M | 0.02 | 3.0% |
| 2020 | CNY 2.14M | 0.02 | 18.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.4:1 on May 12, 2023.
Who owns Shanghai OPM Biosciences Co. Ltd. A
- Insiders 30.98%
- Institutions 28.66%
- Public & others 40.37%
- Shares outstanding 142M
- Free float 104M
Shanghai OPM Biosciences Co. Ltd. A company profile
- Company name
- Shanghai OPM Biosciences Co. Ltd. A
- Ticker
- 688293.SHG
- ISIN
- CNE100005PF1
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 102
- Fiscal year end
- December
- Address
- Building 28, Shanghai, China, 201321
- Phone
- 86 21 2078 0178
- Website
- opmbiosciences.com
About Shanghai OPM Biosciences Co. Ltd. A
Shanghai OPM Biosciences Co., Ltd. provides cell culture media and CDMO services in China and internationally. The company offers cell culture media and feed supplements, such as OPM's CHO-Platform, OPM-293 Platform, OPM-Vac platform, OPM-Hybri Platform, VegaCHO media and feeds, as well as customized cell culture media development services. It also provides end-to-end biologics CDMO services, such as antibody discovery, stable cell line development, cell banking, upstream process development, downstream process development, formulation development, and quality control and product characterization of biologics. The company was founded in 2013 and is headquartered in Shanghai, China.
Shanghai OPM Biosciences Co. Ltd. A management
4- Dr. Zhihua XiaoChairman & GM · born 1974
- Ms. Liangping NiCFO, Accounting Supervisor, Deputy GM & Director · born 1984
- Ms. Yun Fen HeDeputy GM & Director · born 1979
- Ms. Xiaohan MaSecretary to the Board · born 1990